One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

By James C. Yao, Manal M. Hassan, A. Phan, Cecile G. Dagohoy, C. Leary, J. Mares, E. Abdalla, J. Fleming, J. Vauthey, A. Rashid and 1 more. Journal of Clinical Oncology, 2008

4,249 citations recorded by the source corpus.

Subfields: Epidemiology, Neurology, Oncology

View Paper: https://www.semanticscholar.org/paper/d4f1085a9c5b9150f337da17e14290d5d5a4f263

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Pinchot
2. D. Klimstra
3. K. Holen
4. R. Sippel
5. Herbert Chen
6. P. Ferolla
7. Filosso Pl
8. I. Modlin

Citations in the corpus

• Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (2017, neutral): “Decreased appetite 20 (18) 0 9 (8) 3 (3) 0.”
• Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (2014, neutral): “Withdrawal because of adverse event related to study treatment 1 (1) 0”
• Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. (2011, background): “than the expected 33-month survival (95% CI, 31 to 35) in patients with differentiated metastasized neuroendocrine cancer receiving various treatments.(18) Table 2.”
• Exploring the rising incidence of neuroendocrine tumors: A population‐based analysis of epidemiology, metastatic presentation, and outcomes (2015, methodology): “25 cases per year per 100,000).(1) In Europe and Asia, the incidence appears significantly lower and ranges from 1.”
• Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015, background): “However, for both TC and AC, recurrence may not occur until many years later, hence the need for long-term surveillance [2, 18, 21, 54].”
• The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems (2010, methodology): “Data submitted to the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute separated tumors into localized, regional, and distant stages based on the presence of lymph node or distant metastases, but substratification of the extent of the primary tumor was not ”
• Carcinoid Tumors (2008, background): “In fact, when compared with other GI neoplasms, the estimated 29-year limited-duration prevalence of NETs was 103,312 in 2004, making these tumors significantly more common than esophageal cancer (28,664), gastric cancer (65,836), pancreatic cancer (32,353), and hepatobiliary cancer (21,427) in the ”
• Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) (2005, background): “< 4% for distant spread.(14) The histopathological type of the tumour, its Ki-67 or MIB-I proliferation index, size and location, as well as the age of the patient, also affect survival.”
• Everolimus for Advanced Pancreatic Neuroendocrine Tumors (2011, neutral): “Hyperglycemia 27 (13) 11 (5) 9 (4) 4 (2)”